Angiopoietin-2 specific binding agents
Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
1. An isolated antibody comprising a heavy chain and a light chain, said heavy chain comprising a heavy chain variable region of SEQ ID NO: 11 or an antigen binding fragment thereof; and said light chain comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 210, or an antigen binding fragment thereof.
2. An isolated antibody that specifically binds angiopoietin-2 comprising a heavy chain and a light chain, wherein the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 210, or an antigen binding fragment thereof.
3. An isolated antibody, or antigen binding fragment thereof, that specifically binds angiopoietin-2, wherein the antibody comprises a heavy chain and a light chain:
the heavy chain comprising heavy chain framework regions, and a heavy chain variable region, wherein the heavy chain variable region comprises CDR1 (SEQ ID NO:69), CDR2 (SEQ ID NO:111), and CDR3 (SEQ ID NO:150) and
the light chain comprising light chain framework regions, and a light chain variable region, wherein the light chain variable region comprises CDR1 (SEQ ID NO:70), CDR2 (SEQ ID NO:106), and CDR3 (SEQ ID NO:212).
4. The antibody of any of claims 1 , 2 , or 3 , wherein the antibody is an IgG1 antibody.
5. The antibody, or antigen binding fragment thereof of any of claims 1 , 2 , or 3 that is a polyclonal, monoclonal, chimeric, humanized, or fully human antibody.
6. The antigen binding fragment of the antibody of claim 5 comprising a single chain Fv antibody.
7. The antigen binding fragment of the antibody of claim 5 comprising a Fab antibody.
8. The antigen binding fragment of the antibody of claim 5 comprising a F(ab′) 2 antibody.
9. A pharmaceutical composition comprising the antibody of claim 1 , 2 , 3 , 5 , or 6 and a pharmaceutically acceptable formulation agent.